GlaxoSmithKline Pharmaceuticals Limited

rs,

G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sirs, Subject: Presentation of Analyst / Institutional Investor Meetings Pursuant to Regulation 30 read

0.5%

par with market Brand Augmentin Calpol Ceftum T-Bact CCM Trelegy Unit EI (MS G/L %) 102 (+0.5%) 90 (-3%) 112 (+3.1%) 101 (+0.5%) 107 (+0.5%) 118 (+0.8%) Pediatric Vaccines continues to lea

3%

rket Brand Augmentin Calpol Ceftum T-Bact CCM Trelegy Unit EI (MS G/L %) 102 (+0.5%) 90 (-3%) 112 (+3.1%) 101 (+0.5%) 107 (+0.5%) 118 (+0.8%) Pediatric Vaccines continues to lead the ove

3.1%

Augmentin Calpol Ceftum T-Bact CCM Trelegy Unit EI (MS G/L %) 102 (+0.5%) 90 (-3%) 112 (+3.1%) 101 (+0.5%) 107 (+0.5%) 118 (+0.8%) Pediatric Vaccines continues to lead the overall Vx marke

0.8%

M Trelegy Unit EI (MS G/L %) 102 (+0.5%) 90 (-3%) 112 (+3.1%) 101 (+0.5%) 107 (+0.5%) 118 (+0.8%) Pediatric Vaccines continues to lead the overall Vx market Brand Boostrix Varilrix Unit EI (

1.4%

ines continues to lead the overall Vx market Brand Boostrix Varilrix Unit EI (MS G/L %) 102 (+1.4%) 130 (+11.1%) H C A O R P P A K S G E N O D N A G N C R U O S E R C G E T A R T S I I 2100+ Se

11.1%

s to lead the overall Vx market Brand Boostrix Varilrix Unit EI (MS G/L %) 102 (+1.4%) 130 (+11.1%) H C A O R P P A K S G E N O D N A G N C R U O S E R C G E T A R T S I I 2100+ Severe asthma pa

5%

ts benefitted #1 Accelerate Initiation of Nucala #2 Elevate long-term Tx goals for SA patients ~5% MS in SITT class EI 118 Value EI #1 Early optimization #2 Differentiation vs other SITTs Sour

29%

rts for Shingles awareness Win with HCPs Create Vaccinators Educate Consumers Drive Awareness 29% Shingles Awareness ~10K# Monthly Avg Rx Reflection in IQVIA All New Campaign ft. AB In core 50

₹946

d talent to deliver impact #AheadTogether 5 Oct-Dec’24 (Q3 FY25): Financial Highlights Revenue ₹946cr Growth +18% EBITDA ₹290cr Growth +33% Margin: 30.7% PAT (before exceptional) ₹229cr Growt

18%

ver impact #AheadTogether 5 Oct-Dec’24 (Q3 FY25): Financial Highlights Revenue ₹946cr Growth +18% EBITDA ₹290cr Growth +33% Margin: 30.7% PAT (before exceptional) ₹229cr Growth+37% Margin: 2

₹290

AheadTogether 5 Oct-Dec’24 (Q3 FY25): Financial Highlights Revenue ₹946cr Growth +18% EBITDA ₹290cr Growth +33% Margin: 30.7% PAT (before exceptional) ₹229cr Growth+37% Margin: 24%  Strong p